Julie Irving

3.4k total citations
53 papers, 2.0k citations indexed

About

Julie Irving is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Molecular Biology. According to data from OpenAlex, Julie Irving has authored 53 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Public Health, Environmental and Occupational Health, 23 papers in Hematology and 16 papers in Molecular Biology. Recurrent topics in Julie Irving's work include Acute Lymphoblastic Leukemia research (25 papers), Acute Myeloid Leukemia Research (13 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Julie Irving is often cited by papers focused on Acute Lymphoblastic Leukemia research (25 papers), Acute Myeloid Leukemia Research (13 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Julie Irving collaborates with scholars based in United Kingdom, Canada and Germany. Julie Irving's co-authors include Patricia L. Dobkin, Jeeseon Park, Thomas G. Knight, Andrew G. Hall, Zindel V. Segal, Adam K. Anderson, Norman A. S. Farb, Josef Vormoor, Marian Case and Lynne Minto and has published in prestigious journals such as Blood, Cancer Cell and Cancer Research.

In The Last Decade

Julie Irving

51 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie Irving United Kingdom 22 675 597 548 478 278 53 2.0k
Tamme W. Goecke Germany 29 276 0.4× 635 1.1× 119 0.2× 348 0.7× 85 0.3× 108 2.0k
Clayton W. Schupp United States 26 382 0.6× 218 0.4× 127 0.2× 215 0.4× 388 1.4× 38 3.0k
Elizabeth Hill United States 21 160 0.2× 197 0.3× 88 0.2× 254 0.5× 138 0.5× 59 1.4k
Rebecca Evans Australia 20 92 0.1× 283 0.5× 76 0.1× 428 0.9× 272 1.0× 84 1.6k
Jennifer M. Knight United States 21 211 0.3× 116 0.2× 175 0.3× 63 0.1× 275 1.0× 84 1.4k
Emily C. Martin United States 18 88 0.1× 515 0.9× 114 0.2× 131 0.3× 257 0.9× 47 1.8k
James Marriott Canada 22 145 0.2× 139 0.2× 138 0.3× 167 0.3× 243 0.9× 62 2.3k
Laurie Ford United States 23 126 0.2× 110 0.2× 457 0.8× 377 0.8× 320 1.2× 66 1.2k
Anita Yakkundi United Kingdom 20 668 1.0× 79 0.1× 81 0.1× 344 0.7× 189 0.7× 30 1.5k
Ottó Walter Germany 14 452 0.7× 75 0.1× 85 0.2× 104 0.2× 70 0.3× 33 1.3k

Countries citing papers authored by Julie Irving

Since Specialization
Citations

This map shows the geographic impact of Julie Irving's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Irving with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Irving more than expected).

Fields of papers citing papers by Julie Irving

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Irving. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Irving. The network helps show where Julie Irving may publish in the future.

Co-authorship network of co-authors of Julie Irving

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Irving. A scholar is included among the top collaborators of Julie Irving based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Irving. Julie Irving is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mašić, Dino, Marian Case, David McDonald, et al.. (2022). Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia. Haematologica. 108(4). 981–992. 6 indexed citations
2.
Parker, Catriona, Shekhar Krishnan, Julie Irving, et al.. (2019). Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. The Lancet Haematology. 6(4). e204–e216. 34 indexed citations
3.
Berry, Philip, Julie Errington, Jizhong Liu, et al.. (2019). Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial. European Journal of Cancer. 120. 75–85. 21 indexed citations
4.
Doan, Minh, Marian Case, Dino Mašić, et al.. (2017). Label-Free Analyses of Minimal Residual Disease in ALL Using Deep Learning and Imaging Flow Cytometry. Blood. 130. 1437–1437. 2 indexed citations
5.
Farb, Norman A. S., Adam K. Anderson, Arun Ravindran, et al.. (2017). Prevention of relapse/recurrence in major depressive disorder with either mindfulness-based cognitive therapy or cognitive therapy.. Journal of Consulting and Clinical Psychology. 86(2). 200–204. 69 indexed citations
6.
Pal, Deepali, Marian Case, Julie Irving, et al.. (2016). BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance. Klinische Pädiatrie. 228(3). 2 indexed citations
7.
8.
Irving, Julie. (2015). Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia. British Journal of Haematology. 172(5). 655–666. 22 indexed citations
9.
Al‐Balool, Haya H., David Weber, Yilei Liu, et al.. (2011). Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. Genome Research. 21(11). 1788–1799. 37 indexed citations
10.
Hunter, Jill V., Elaine Willmore, Julie Irving, et al.. (2011). NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene. 31(2). 251–264. 34 indexed citations
11.
Nicholson, Lindsay, Thomas G. Knight, Elizabeth Matheson, et al.. (2011). Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes Chromosomes and Cancer. 51(3). 250–256. 12 indexed citations
12.
Zhao, Yan, M. Squires, Hing Y. Leung, et al.. (2011). Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leukemia Research. 35(9). 1233–1240. 11 indexed citations
13.
14.
15.
Irving, Julie, Patricia L. Dobkin, & Jeeseon Park. (2009). Cultivating mindfulness in health care professionals: A review of empirical studies of mindfulness-based stress reduction (MBSR). Complementary Therapies in Clinical Practice. 15(2). 61–66. 392 indexed citations
16.
17.
Case, Marian, Elizabeth Matheson, Lynne Minto, et al.. (2008). Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia. Cancer Research. 68(16). 6803–6809. 90 indexed citations
18.
Walker, Brian A., Matthew Jenner, Nicholas J. Dickens, et al.. (2008). MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 94(1). 78–86. 95 indexed citations
19.
Hotfilder, Marc, Simon Bomken, Kerrie Wilson, et al.. (2008). In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties. Cancer Cell. 14(1). 47–58. 179 indexed citations
20.
Rowe, David W., et al.. (1996). A case of mature B‐cell ALL with coexistence of t(1;19) and t(14;18) and expression of the E2A/PBX1 fusion gene. British Journal of Haematology. 94(1). 133–135. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamme W. Goecke Breakdown of academic impact, for papers by Clayton W. Schupp Breakdown of academic impact, for papers by Elizabeth Hill Breakdown of academic impact, for papers by Rebecca Evans Breakdown of academic impact, for papers by Jennifer M. Knight Breakdown of academic impact, for papers by Emily C. Martin Breakdown of academic impact, for papers by James Marriott Breakdown of academic impact, for papers by Laurie Ford Breakdown of academic impact, for papers by Anita Yakkundi Breakdown of academic impact, for papers by Ottó Walter
Rankless by CCL
2026